These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 20106343)

  • 1. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W; Ziemssen T
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T; Schrempf W
    Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
    Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
    Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
    Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
    Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.
    Racke MK; Lovett-Racke AE
    J Immunol; 2011 Feb; 186(4):1887-90. PubMed ID: 21289312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation by the copolymer glatiramer acetate.
    Arnon R; Sela M
    J Mol Recognit; 2003; 16(6):412-21. PubMed ID: 14732933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.
    Hestvik AL; Skorstad G; Price DA; Vartdal F; Holmoy T
    Mult Scler; 2008 Jul; 14(6):749-58. PubMed ID: 18611988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate.
    Comi G; Moiola L
    Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
    Aharoni R
    Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.
    Aharoni R; Eilam R; Stock A; Vainshtein A; Shezen E; Gal H; Friedman N; Arnon R
    J Neuroimmunol; 2010 Aug; 225(1-2):100-11. PubMed ID: 20554028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite.
    Platten M; Ho PP; Youssef S; Fontoura P; Garren H; Hur EM; Gupta R; Lee LY; Kidd BA; Robinson WH; Sobel RA; Selley ML; Steinman L
    Science; 2005 Nov; 310(5749):850-5. PubMed ID: 16272121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
    Ziemssen T; Kümpfel T; Schneider H; Klinkert WE; Neuhaus O; Hohlfeld R
    J Neurol Sci; 2005 Jun; 233(1-2):109-12. PubMed ID: 15869765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
    Salama HH; Hong J; Zang YC; El-Mongui A; Zhang J
    Brain; 2003 Dec; 126(Pt 12):2638-47. PubMed ID: 12937077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
    Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
    CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.